JPM: Jazz eyes a 'dramatic' shift to new-drug revenue by 2022, CEO says

Jazz Pharmaceuticals is in the middle of a four-product launch cycle—one in 2019, two in 2020 and one more targeted for 2021—and a dramatic shift for the small pharma.

For years, Jazz has depended on Xyrem to fuel its growth, but 2021 will change that. Thanks to the new drugs, plus launches in new markets and new indications, more than half of Jazz's revenue will come from new drugs by 2022, CEO Bruce Cozadd said.